In this newsletter, it is discussed how semaglutide is effective in treating osteoarthritis, TMS shows promise in slowing Alzheimer’s disease, and the top executives of AstraZeneca in China are under investigation. Earnings reports from companies like Amgen, Regeneron Pharma, and Merck are highlighted, along with the delay in the release of Compass Pathways’ study on psilocybin for depression. There is also a focus on CRISPR gene editing and the key players in this field. Additionally, a small study on the potential of TMS in Alzheimer’s is mentioned, along with the news of Jade Biosciences going public through a merger.
Source link
Readout Newsletter: Amgen, Regeneron, Wegovy/Ozempic news
